ERBB2-Low (Also Known as HER2-Low) Breast Cancer
Menée à partir des données du registre national américain des cancers portant sur 1 136 016 patients atteints d'un cancer du sein (âge moyen : 62,4 ans ; 99,1 % de femmes), cette étude analyse, en fonction du statut ERBB2 de la tumeur, les caractéristiques clinicopathologiques de la maladie, la réponse aux chimiothérapies néoadjuvantes et la survie globale des patients
Breast cancer is classified based on the presence or absence of : Estrogen receptor (ER) protein on cancer cells, Progesterone receptor (PR) protein on cancer cells, Amplification of human epidermal growth factor receptor 2 (ERBB2, also known as HER2) (extra copies of the gene in cancer cells). If ER and PR are expressed, this is considered hormone receptor (HR)–positive breast cancer. If ERBB2 is amplified or overexpressed, this is considered ERBB2-positive breast cancer. If a breast cancer lacks all of these features, it is considered “triple-negative.”
JAMA Oncology , commentaire en libre accès, 2022